← Back to Search

Nerve Block for Hip Arthritis

Phase 2
Waitlist Available
Led By Jinlei Li, MD PhD FASA
Research Sponsored by Yale University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 72 hours
Awards & highlights

Study Summary

This study is evaluating whether a combination of a local anesthetic and glucocorticoids may help reduce pain following hip surgery.

Eligible Conditions
  • Hip Arthritis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 72 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 72 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Daily Opioid Consumption
Secondary outcome measures
Brief Pain Inventory: Interference
Change in Pain Intensity While in Hospital
Harris Hip Score
+1 more

Side effects data

From 2013 Phase 4 trial • 160 Patients • NCT01163214
33%
Urinary Retention
24%
Vomiting
4%
Fall
4%
Syncope
3%
Pneumonia
3%
Urinary Tract Infection
1%
Stroke Middle Cerebral Artery
1%
Acute Pulmonary Embolism
1%
Acute Renal Failure
1%
Lumbar Vertebral Fracture After Fall
100%
80%
60%
40%
20%
0%
Study treatment Arm
Nerve Block
Periarticular Injection

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Group 1 patients will receive nerve block per standard of careExperimental Treatment2 Interventions
Nerve blocks (QLB/LFCNB) to be placed preoperatively with dexamethasone sodium phosphate (DEX) and methylprednisolone acetate (MPA), per standard of care of anesthesia block service. QLB: 40ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA; and LFCNB: 20ml 0.2% ropivacaine with 5 mg DEX/ 40 mg MPA Preoperatively, Group 1 patients will receive nerve block per standard of care as stated above. Intraoperatively, Group 1 will NOT receive PAI.
Group II: Group 2 will NOT receive any nerve blocks.Active Control3 Interventions
Intraoperatively, the surgeon will perform PAI with exactly the same medication as group 1, ie, 60 ml 0.2% ropivacaine and 10 mg DEX/ 80 mg MPA, per standard of care of Surgeon.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nerve Block
2019
Completed Phase 4
~480
Ropivacaine
2017
Completed Phase 4
~1960

Find a Location

Who is running the clinical trial?

Yale UniversityLead Sponsor
1,848 Previous Clinical Trials
2,737,626 Total Patients Enrolled
Jinlei Li, MD PhD FASAPrincipal InvestigatorYale University

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty
2019. "Periarticular Injection Versus Peripheral Nerve Block in Total Hip Arthroplasty". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03977454.
~35 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top